Clinical trials: Head and Neck Squamous Cell Carcinomas
Head and Neck Cancer, Precancerous/Nonmalignant Condition
Photodynamic Therapy With Porfimer Sodium in Treating Patients With Precancerous Lesions, Cancer, or Other Disease of the Aerodigestive Tract
RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, precancerous cells and cancer cells are killed.
- Trial name
- NCT00453336
- Testing
- Porfimer Sodium, Photodynamic Therapy
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Miami
Head and Neck Cancer, Squamous Cell Carcinoma
Prognostic Immune Biomarkers in HNSCC
Evaluation of the prognostic potential of tumor-infiltrating lymphocytes and PD-L1 expression in non-metastatic squamous cell carcinoma of the head and neck
- Trial name
- NCT05941676
- Testing
- Tumour immunoprofile evaluation
- Where
- Czechia
- Volunteers
- 55 people
- Sponsor
- University Hospital Ostrava
Esophageal Squamous Cell Carcinoma
PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCC
Concurrent chemoradiotherapy is now considered to be the standard treatment modality for esophageal cancer patients who are medically unfit for surgery.
- Trial name
- NCT06186609
- Testing
- PD-1 inhibitor 200mg per three to four weeks, for one year
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Affiliated Hospital of Nantong University
Head and Neck Cancer Squamous Cell Carcinoma
Immunotherapy and Nodal-Sparing Irradiation for T-Cell Induction and Unmasking of Tumor Antigenicity in the Microenvironment for Head and Neck Cancer
This is a non-comparative randomized Phase 2 study using the INITIUM regimen with or without elective nodal irradiation (ENI) delivered before surgery for resectable head and neck squamous cell carcinoma (HNSCC).
- Trial name
- INITIUM (NCT07773987)
- Testing
- Pembrolizumab, Radiotherapy, ENI
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Medical College of Wisconsin
Colorectal Cancer Metastatic, Squamous Cell Carcinoma of Head and Neck
A Phase 1b Study of WU-NK-101 in Combination With Cetuximab
This study is a Phase 1b open-label study designed to characterize the safety, tolerability, and preliminary anti-tumor activity of WU-NK-101 in combination with cetuximab in patients with advanced and/or metastatic CRC (Cohort…
- Trial name
- NCT05674526
- Testing
- WU-NK-101 - Dose Escalation, Cetuximab - Dose Escalation, WU-NK-101 - Cohort Expansion
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Allotera Therapeutics
Esophageal Squamous Cell Carcinoma (ESCC)
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
The purpose of this study was to evaluate the efficacy and safety of tislelizumab as second line treatment in participants with advanced unresectable/metastatic ESCC that had progressed during or after first line therapy.
- Trial name
- NCT03430843
- Testing
- Tislelizumab, Paclitaxel, Docetaxel
- Where
- 104 sites in United States, Belgium and 9 more
- Volunteers
- 512 people
- Sponsor
- BeiGene
Carcinoma, Squamous Cell, Cancer of the Head and Neck
Dose Escalation Study of Hyperbaric Oxygen With Radiation and Chemotherapy to Treat Squamous Cell Carcinoma of the Head and Neck
This research is being done because we do not know the best treatment for advanced Squamous Cell Carcinoma of the Head and Neck.
- Trial name
- HBO-XRT (NCT00474825)
- Testing
- Hyperbaric Oxygen Therapy, Hyperbaric Oxygen
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Baromedical Services
Solid Tumors
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-5552 monotherapy in adult participants with relapsed/refractory solid tumors…
- Trial name
- NCT04774952
- Testing
- RMC-5552
- Where
- 8 sites in United States
- Volunteers
- 58 people
- Sponsor
- Revolution Medicines, Inc.
Melanoma, Non-small Cell Lung Cancer
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma
- Trial name
- NCT07115043
- Testing
- AZD6750, rilvegostomig
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
HNPCC
A Prospective, Single-arm, Phase II Clinical Trial of Becotatug Vedotin for Injection Combined With Pucotenlimab Injection as a First-line Treatment for Platinum-intolerant Advanced Head and Neck Squamous Cell Carcinoma
This study is a randomized, open-label, multi-center phase II trial evaluating the efficacy and safety of the becotatug vedotin in combination with pucotenlimab regimen in patients with advanced head and neck squamous cell…
- Trial name
- NCT07628855
- Testing
- Becotatug Vedotin (recombinant humanized anti-EGFR mAb-MMAE conjugate) combined with Pucotenlimab (recombinant humanized anti-PD-1 mAb)
- Volunteers
- 30 people
- Sponsor
- Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Advanced Solid Tumors, NSCLC
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Based on the overwhelming positive response to this survey and the large number of patients being treated with PD-1/PD-L1 therapy in the UPMC system, the investigators are proposing a trial that will randomize patients who have…
- Conditions
- Advanced Solid Tumors, NSCLC, Bladder Cancer, HNSCC
- Trial name
- NCT04157985
- Testing
- Continue PD-1/PD-L1 Inhibitors treatment, Discontinue PD-1/PD-L1-1 inhibitor
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- Dan Zandberg
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
A Pilot Study of Glutamine PET Imaging of Head and Neck Squamous Cell Carcinoma
We propose a focused, prospective pilot clinical imaging trial to evaluate 11C-Gln PET/CT followed by 18F-FSPG PET/CT in 20 HNSCC patients. Imaging metrics that are common to PET (e.g. SUVmax, peak or mean) will be determined.
- Trial name
- NCT05322135
- Testing
- 18F-FSPG, 11C-Glutamine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7
Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer
This phase Ib trial studies the side effects and best dose of ipilimumab when given together with cetuximab and intensity-modulated radiation therapy (IMRT) in treating patients with previously untreated stage III-IVB head and…
- Conditions
- Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7
- Trial name
- NCT01935921
- Testing
- Cetuximab, Intensity-Modulated Radiation Therapy, Ipilimumab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma
Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer
This phase I trial studies the side effects and best dose of stereotactic body radiation therapy (SBRT) in treating participants with head and neck cancer that has spread from where it started to nearby tissue or lymph nodes and…
- Conditions
- Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma
- Trial name
- NCT02388932
- Testing
- Stereotactic Body Radiation Therapy, Positron Emission Tomography, Computed Tomography
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Case Comprehensive Cancer Center
Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer
Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab
This is a single center, open-label phase I clinical trial designed to determine the safety of personalized and adjusted neoantigen peptide vaccine (PANDA-VAC) administered concurrently with pembrolizumab in subjects with…
- Conditions
- Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- PANDA-VAC (NCT04266730)
- Testing
- PANDA-VAC, Pembrolizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non-small Cell Lung Cancer (NSCLC), Squamous Oesophageal Cancer
A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1
This clinical trial is looking at two new vaccines called ChAdOx1-MAGEA3-NYESO, MVA-MAGEA3 and MVA-NYESO given with patients' standard of care treatment (chemotherapy and an immune checkpoint inhibitor).
- Trial name
- NCT04908111
- Testing
- ChAdOx1-MAGEA3-NYESO (Route = IM injection, Dose = 5×10^10 vp), MVA-MAGEA3 (Route = IM injection, Dose = 1.3×10^8 pfu), Standard of care treatment
- Where
- 9 sites in United Kingdom
- Volunteers
- 15 people
- Sponsor
- Cancer Research UK
Neoplasms, Head and Neck
Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck
This study is being conducted to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in adult subjects with squamous cell carcinoma of the head and neck (SCCHN).
- Trial name
- NCT00725764
- Testing
- GSK1363089 (foretinib)
- Where
- 11 sites in United States
- Volunteers
- 14 people
- Sponsor
- GlaxoSmithKline
Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck
Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck
This multicentre, open-label, Phase 1b/2 study is designed as a 2 part study consisting of a dose-escalation, safety run-in Part A and a dose-expansion Part B
- Trial name
- NCT02499328
- Testing
- AZD9150, MEDI4736, AZD5069
- Where
- 44 sites in United States, Belgium and 4 more
- Volunteers
- 340 people
- Sponsor
- AstraZeneca
Laryngeal Squamous Cell Carcinoma
Decisional Regret in Open Partial Horizontal Laryngectomy
Prospective multicentric study to evaluate decisional regret and psychometric and functional outcomes in patient previously treated with Open Horizontal partial Laryngectomy
- Trial name
- NCT06805071
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Head and Neck Squamous Cell Carcinoma
Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
The investigators hypothesize that inhibition of angiogenesis and PD-1 will be more effective than inhibition of PD-1 alone. The first step in pursuing proof of this hypothesis is to establish the safety and feasibility of…
- Trial name
- NCT03650764
- Testing
- Ramucirumab, Pembrolizumab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Washington University School of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.